Hepatocellular Carcinoma
Rivoceranib Plus Camrelizumab NDA for Unresectable HCC is Accepted by the FDA
SG Tylor
Source – Elevar therapeutics On July 17, 2023, The FDA has accepted a New Drug Application (NDA) for rivoceranib, an ...
Initiation of Treatment with TTI-101, Either Alone or in Combination with Standard Targeted Therapy, in Advanced Hepatocellular Carcinoma
SG Tylor
Source – Tvardi Therapeutics On June 22, 2023 the initial administration of TTI-101, either as a monotherapy or in combination ...
